Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 125Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 11Sulperazon

PharmaCompass

01

Brand Name : Sulperazon

Cefoperazone

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone

Main Therapeutic Indication : Nephrology

Currency : USD

2019 Revenue in Millions : 684

2018 Revenue in Millions : 613

Growth (%) : 12

blank

02

Brand Name : Sulperazon

Cefoperazone

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone

Main Therapeutic Indication : Nephrology

Currency : USD

2020 Revenue in Millions : 618

2019 Revenue in Millions : 684

Growth (%) : -10

blank

03

Brand Name : Sulperazon

Cefoperazone

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone

Main Therapeutic Indication : Nephrology

Currency : USD

2021 Revenue in Millions : 683

2020 Revenue in Millions : 618

Growth (%) : 11

blank

04

Brand Name : Sulperazon

Cefoperazone

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2022 Revenue in Millions : 786

2021 Revenue in Millions : 683

Growth (%) : 15

blank

05

Brand Name : Sulperazon

Cefoperazone

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2023 Revenue in Millions : 757

2022 Revenue in Millions : 786

Growth (%) : -4

blank

06

Brand Name : Sulperazon

Cefoperazone/Sulbactam

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone/Sulbactam

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2024 Revenue in Millions : 637

2023 Revenue in Millions : 757

Growth (%) : -16

blank

07

Brand Name : Sulperazon

Cefoperazone and Sulbactam

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone and Sulbactam

Main Therapeutic Indication : Urology

Currency : USD

2014 Revenue in Millions : 14.90%

2013 Revenue in Millions :

Growth (%) :

blank

08

Brand Name : Sulperazon

Cefoperazone and Sulbactam

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone and Sulbactam

Main Therapeutic Indication : Urology

Currency : USD

2015 Revenue in Millions : 354

2014 Revenue in Millions : 339

Growth (%) : -4%

blank

09

Brand Name : Sulperazon

Cefoperazone And Sulbactam

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone And Sulbactam

Main Therapeutic Indication : Urology

Currency : USD

2016 Revenue in Millions : 396

2015 Revenue in Millions : 339

Growth (%) : 17

blank

10

Brand Name : Sulperazon

Cefoperazone and Sulbactam

arrow
APGA Annual Conference
Not Confirmed

Brand Name : Sulperazon

arrow
APGA Annual Conference
Not Confirmed

Cefoperazone and Sulbactam

Main Therapeutic Indication : Urology

Currency : USD

2017 Revenue in Millions : 471

2016 Revenue in Millions : 396

Growth (%) : 19

blank